A fully integrated CDMO platform combining precision fermentation, metabolic engineering, and synthetic chemistry — seamlessly scaling from early research to commercial API production.
From molecular design to scalable GMP-ready processes
Bioplus Life Sciences provides a fully integrated CDMO platform for the development and manufacturing of Active Pharmaceutical Ingredients. Our differentiation lies in the seamless integration of precision fermentation, metabolic engineering, and synthetic chemistry within a unified ecosystem.
Driven by a rigorous Quality by Design (QbD) framework, we design robust, reproducible processes aligned with global regulatory expectations — enabling efficient development and scalable manufacturing from early-stage research to commercial production.
APIs, amino acids, metabolites, fatty acid derivatives, biopolymers, vitamins
E. coli, Pichia, Streptomyces, Yeasts, Fungi, Microalgae
Our process development platform bridges the gap between early-stage innovation and global regulatory success, anchored in strong Regulatory Starting Material (RSM) strategies.
Engineering high-performance production systems using advanced genetic tools across bacteria, yeast, fungi, and algal platforms for optimized yields and consistency.
Precise pathway engineering to reprogram cellular metabolism, enhancing productivity and selectivity for efficient, sustainable, and scalable bio-based manufacturing.
Highly iterative and reproducible strains and chemical routes that transition seamlessly from lab development to cGMP-compliant manufacturing at commercial scale.
Chemical synthesis and fermentation at commercial scale
Our Hosur facility focuses on the development and manufacturing of APIs and complex drug intermediates, combining advanced chemical synthesis with efficient process design for consistent quality at global scale.
Advanced fermentation manufacturing forms a core part of our integrated API platform at Hosur, enabling scalable production through precision microbial processes.
Integrated strain development and process optimization frameworks ensure reproducibility, tight process control, and consistent product quality aligned with pharmaceutical specifications.
Biocatalysis, enzymatic routes, and sustainable process innovation
Bioplus integrates environmentally responsible approaches into process development and manufacturing through sustainable chemistry and biocatalytic technologies — reducing environmental footprint without compromising quality or yield.
Processes are designed to limit the use of heavy metal catalysts and chlorine-based chemistry, reducing hazardous emissions and supporting global compliance. We work toward synthesis of alternative proteins and APIs through sustainable pathways and genetic engineering.
We work toward the synthesis of alternative proteins and APIs through sustainable pathways and genetic engineering, pioneering the next generation of bio-based pharmaceuticals.
Real-world proof of our integrated API platform at work
Real-world examples of how our integrated API platform delivers breakthrough solutions — combining sustainability, efficiency, and scientific excellence.
The critical deacylation step in sucralose manufacturing was transitioned from a traditional chemical process to a specialized enzymatic process, fundamentally transforming the production pathway.
This shift resulted in the complete elimination of hazardous chemicals, significantly reducing the environmental footprint of the facility and achieving full compliance with green chemistry principles.
The enzymatic route greatly simplified the workflow and ensured the process was completed without unwanted impurity formation, achieving high regio- and stereoselectivity.
A flagship oral NCE was originally developed via a multi-step synthetic process and successfully scaled to pilot levels, demonstrating the molecule's commercial potential.
To meet anticipated global demand and prioritize sustainability, Bioplus collaborated with premier international universities to develop a non-hazardous alternative production route.
A proprietary recombinant technology was established to produce the drug via microbial fermentation. The current biotech-derived process produces a highly pure API with 4× the yield of the original synthetic method, utilizing sustainable bio-based inputs. The process was patented by Bioplus.
High-quality chemical intermediates for pharmaceutical synthesis — manufactured at our integrated Hosur campus using both fermentation-derived and synthetic chemistry processes.
Leveraging our co-located fermentation and chemical manufacturing units at the 16-acre Hosur campus, we deliver high-purity pharmaceutical intermediates with seamless batch-to-batch consistency at commercial scale.
Our integrated upstream and downstream processing capabilities ensure efficient purification, analytical characterisation, and documentation aligned with global regulatory expectations.